ARL67156 triethylamine FPL 67156 triethylamine|西域试剂

ARL67156 triethylamine FPL 67156 triethylamine,98.0%

产品编号：Bellancom-103265D| 分子式：C₁₅H₂₄Br₂N₅O₁₂P₃.(4.3C₆H₁₅N)| 分子量：1154.23

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-103265D	￥1800.00	杭州北京（现货）
Bellancom-103265D	￥6500.00	杭州北京（现货）
Bellancom-103265D	￥10400.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

ARL67156 triethylamine FPL 67156 triethylamine

产品介绍

ARL67156 (FPL 67156) triethylamine 是一种 ecto-ATPase 抑制剂。ARL67156 triethylamine 是竞争性 NTPDase1 (CD39)，NTPDase3 和 NPP1 抑制剂，K_i 分别为 11，18 和 12 μM。ARL67156 triethylamine 可用于钙化性主动脉瓣疾病、哮喘等疾病的研究。

生物活性

ARL67156 (FPL 67156) triethylamine is a selective ecto-ATPase inhibitor. ARL67156 triethylamine is a competitive inhibitor of NTPDase1 (CD39), NTPDase3 and NPP1, with K_is of 11, 18 and 12 μM, respectively. ARL67156 triethylamine can be used in the research of disease like calcific aortic valve disease, asthma.

体外研究

ARL67156 triethylamine (1-100 μM) potentiates neurogenic contractions in a concentration-dependent manner^[4].
ARL67156 triethylamine (10 μg/mL, 24 h) increases the surface expression of CXCR3 on ATP-treated HMC-1 cells^[5].
ARL67156 triethylamine (30 μM, 5s) potentiates the norepinephrine release promoted by ATP in guinea pig heart synaptosomes^[6].
ARL67156 triethylamine (100 μM, 4h) significantly decreases HIV-1replication in macrophages^[7].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

ARL67156 triethylamine (1.1 μg/kg/day, administered with osmotic pumps implanted subcutaneously, for 28 days) prevents the development of calcific aortic valve disease in Warfarin (HY-B0687)-treated rats.
ARL67156 triethylamine (intraperitoneal injection, 2 mg/kg) prevents the increase of serum adenosine concentration induced by Fructose 1,6-bisphosphate (FBP).

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Warfarin-induced mineralization rat model
Dosage:	1.1 μg/kg/day
Administration:	Administered with osmotic pumps implanted subcutaneously, for 28 days
Result:	Prevented the development of aortic stenosis by lowering the level of apoptosis and mineralization of the aortic valve/aorta. Normalized the level of pAkt (an important kinase involved in the survival pathway).

Animal Model:	C57BL/6 mice
Dosage:	2 mg/kg
Administration:	Intraperitoneal injection, 1 h before administration of FBP (100 mg/kg)
Result:	Completely abolished the anti-inflammatory effects of FBP (observed by the neutrophil infiltration, hyperalgesia and oedema of the joint).

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Warfarin-induced mineralization rat model
Dosage:	1.1 μg/kg/day
Administration:	Administered with osmotic pumps implanted subcutaneously, for 28 days
Result:	Prevented the development of aortic stenosis by lowering the level of apoptosis and mineralization of the aortic valve/aorta. Normalized the level of pAkt (an important kinase involved in the survival pathway).

Animal Model:	C57BL/6 mice
Dosage:	2 mg/kg
Administration:	Intraperitoneal injection, 1 h before administration of FBP (100 mg/kg)
Result:	Completely abolished the anti-inflammatory effects of FBP (observed by the neutrophil infiltration, hyperalgesia and oedema of the joint).

性状

Solid

溶解性数据

In Vitro:

Methanol : 125 mg/mL (108.30 mM; Need ultrasonic)

DMSO : 100 mg/mL (86.64 mM; Need ultrasonic)

H₂O : 100 mg/mL (86.64 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	0.8664 mL	4.3319 mL	8.6638 mL
5 mM	0.1733 mL	0.8664 mL	1.7328 mL
10 mM	0.0866 mL	0.4332 mL	0.8664 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (2.17 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (2.17 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (2.17 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (2.17 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。